Company Encyclopedia
View More
name
Senti Biosciences
SNTI.US
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company’s product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells.
1.912 T
SNTI.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Senti Biosciences Announces New Employment Inducement Grants | SNTI Stock News

    Senti Biosciences announced new employment inducement grants effective December 12, 2025. The Board granted stock options for 13,680 shares at $1.31 per share to a new employee under the Amended and Restated 2022 Inducement Equity Plan. These grants were made as inducement material for employment, in line with NASDAQ Listing Rule 5635(c)(4). Senti Bio is a biotechnology company developing cell and gene therapies using its Gene Circuit platform.

    StockTitan·
    US
    SNTI
    +2.56%
    StockTitan·
    US
    SNTI
    +2.56%

    Pre-market hot trades in US stocks: Reto Eco-Solutions pre-market down 13.54%; Senti Biosciences pre-market up 12.34%

    Reto Eco-Solutions pre-market down 13.54%; Senti Biosciences pre-market up 12.34%; A SPAC III Acquisition pre-market up 214.31%; Enveric Biosciences pre-market up 79.90%; Biodexa Pharmaceuticals pre-market up 77.40%

    Tracking Unusual Activity·
    US
    RETO
    +2.91%
    US
    SNTI
    +2.56%
    Tracking Unusual Activity·
    US
    RETO
    +2.91%
    US
    SNTI
    +2.56%

    Senti Biosciences shares are trading higher after the company announced new data from its ongoing multinational, multicenter clinical trial of SENTI-202

    benzinga_article·
    US
    SNTI
    +2.56%
    benzinga_article·
    US
    SNTI
    +2.56%

    Why Is Senti Biosciences Stock (SNTI) Up Today?

    Senti Biosciences (SNTI) stock surged after announcing positive data from its SENTI-202 clinical trial for Acute Myeloid Leukemia. The trial showed a 50% Overall Response Rate and 42% complete remission at the recommended Phase 2 dose. The therapy was well tolerated with no dose-limiting toxicities. Following this news, SNTI stock rose 22.59% in pre-market trading, with heavy trading volume. The stock had previously fallen 31.91% year-to-date.

    Tip Ranks·
    US
    SNTI
    +2.56%
    Tip Ranks·
    US
    SNTI
    +2.56%

    Senti Biosciences Reports Promising Clinical Results for SENTI-202 in AML Trial

    Senti Biosciences Inc. announced that its investigational CAR-NK cell therapy, SENTI-202, received RMAT designation from the FDA for treating relapsed or refractory hematologic malignancies, including AML. This follows promising results from a Phase 1 trial, showing a 50% overall response rate and 42% complete remission at the recommended Phase 2 dose. SENTI-202 also received Orphan Drug Designation earlier in June 2025. The data was presented at the ASH Annual Meeting on December 8, 2025.

    Reuters·
    US
    SNTI
    +2.56%
    Reuters·
    US
    SNTI
    +2.56%
    Posts
    View More

    Hello stock fans some names moving higher in premarket $Photronics(PLAB.US) $Horizon Space Acquisition I(HSPO.US) $Braze(BRZE.US) $GE Vernova LLC(GEV.US) $Abivax SA(ABVX.US) $AKT $Jumia Tech AG (JMIA...........................

    © 2025 Longbridge｜Disclaimer